Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Articles by Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Future Directions in Biomarker-Based Oncology

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

May 12th 2021

Experts in oncology discuss future directions in biomarker-driven therapy.

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

ByMark A. Socinski, MD, Advent Health Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

May 12th 2021

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Tumor Agnostic RET Inhibition: The ARROW Trial

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

May 5th 2021

Dr Jyoti Patel presents data from the ARROW clinical trial.

Tumor Agnostic RET Inhibition: The LIBRETTO-001 Trial

ByMark A. Socinski, MD, Advent Health Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

May 5th 2021

Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.

RET as a Therapeutic Target for Solid Tumors

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, John Hopkins Sidney Kimmel Cancer Center

April 28th 2021

Expert oncologists discuss RET-driven therapy for select solid tumors.

TRK Fusion Inhibitors in Tumor-Agnostic Clinical Trials

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 21st 2021

Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.

Treatment Options for NRTK Fusion–Positive Solid Tumors

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 21st 2021

Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.

NRTK Fusions in Oncology

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 14th 2021

Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.

Solid Tumors: Unmet Needs Related to Biomarker-Driven Therapy

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 14th 2021

Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.

Companion Diagnostics in Oncology for Solid Tumors

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 7th 2021

Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors.

Pan-Tumor Biomarker Testing in Oncology

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center,Lori J. Wirth, MD, Massachusetts General Hospital,Jyoti Patel, MD, FASCO, Lurie Cancer Center at Northwestern Medicine,Benjamin P. Levy, MD, Johns Hopkins Kimmel Cancer Center

April 7th 2021

A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.

Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Articles by Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center

Future Directions in Biomarker-Based Oncology

NRG1 Fusions in Solid Tumors: The CRESTONE Trial

Tumor Agnostic RET Inhibition: The ARROW Trial

Tumor Agnostic RET Inhibition: The LIBRETTO-001 Trial

RET as a Therapeutic Target for Solid Tumors

TRK Fusion Inhibitors in Tumor-Agnostic Clinical Trials

Treatment Options for NRTK Fusion–Positive Solid Tumors

NRTK Fusions in Oncology

Solid Tumors: Unmet Needs Related to Biomarker-Driven Therapy

Companion Diagnostics in Oncology for Solid Tumors

Pan-Tumor Biomarker Testing in Oncology

Latest Updated Articles

Trending on OncLive

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer

Real-World SEER Data Highlight Age-Related Survival Gap in ICI-Treated Advanced RCC